Crizanlizumab for RVCL

Crizanlizumab for RVCL

Brief description of study

Retinal vasculopathy with cerebral leukoencephalopathy (RVCL) is a very rare and fatal genetic condition that affects the smallest blood vessels, especially of the brain and eye. It causes damage in the brain and eye, and there is currently no treatment to reduce these areas of damage. Crizanlizumab has been shown to treat similar symptoms in other diseases, and it's hypothesized that treating RVCL patients with crizanlizumab will slow the progression of this damage.

Patients diagnosed with retinal vasculopathy with cerebral leukoencephalopathy (RVCL) by Dr. Jonathan Miner at Washington University in St. Louis are being invited to participate in this study at Penn Medicine. Patients that live close to Penn Medicine will be seen by the research team due to proximity of location.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Retina,retinal vasculopathy
  • Age: Between 18 Years - 99 Years
  • Gender: All


Updated on 12 Jun 2023. Study ID: 844604

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center